Novel Therapy for Diabetes, Dyslipidemia and Obesity

Description

Researchers at the University of Alberta have discovered a potential therapy to prevent dyslipidemia, obesity, diabetes and atherosclerosis. The study shows that depletion of an enzyme inhibits phosphatidylcholine synthesis in mice which results in decreased levels of blood cholesterol and triglycerides. Associated mechanisms, which include large increases in the hormone GLP-1 following a meal, protect […]

Novel Bio-markers for Diagnosis and Treatment of Stress

Description
Dr. Dean Befus at the University of Alberta in collaboration with Dr. Thomas Ritz at the Southern Methodist University have identified calcium-binding protein spermatid specific 1 (CABS1) protein forms that can be used as predictive, diagnostic, and prognostic biomarkers for stress in humans.
BACKGROUND
Cortisol is one of the best known and most widely used biomarkers for […]

Photocleavable Affinity Tags for Ultra Pure Protein Purification

Description
Affinity tags are highly efficient tools for purifying proteins from crude extracts. However, most affinity purification elusion schemes require a change in buffer condition, such as addition of imidazole or a decrease in pH. This change in buffer conditions may cause some proteins that are non-specifically bound to the resin to elute as contaminants and […]

Fluorinated Fructose Derivatives for PET Imaging

Description
Positron emission tomography (PET) is a non-invasive nuclear medicine imaging technique that produces a three-dimensional image of physiological processes and tissue microenvironments, which is used fordiagnosing and/or treating diseases including cancer, heart disease, and brain abnormalities. Traditionally,tumour imaging with PET relies on the use of the glucose analogue 2-deoxy-2-fluoro-D-glucose(FDG) as the imaging agent, which takes […]

Novel precursors for the PET radiotracer [18F]FAZA

Description
FAZA is a PET radiotracer that selectively accumulates in hypoxic cells. It was invented and developed at the Cross Cancer Institute of Alberta and is currently used in several medical centers to assess tumor hypoxia in cancer patients. FAZA shows improved tracer pharmacokinetics in comparison to other ‘first generation’ clinical hypoxia PET tracers, giving higher […]